Form 4: NeuroOne Director Mills Receives Equity Grant

Jason Richard Mills, a Director at NeuroOne Medical Technologies Corp., was granted 7,758 shares of common stock and options to purchase 4,806 shares, vesting over one year.

Summary

• Jason Richard Mills, a Director of NEUROONE MEDICAL TECHNOLOGIES Corp. (NMTC), acquired common stock and derivative securities.
• The transaction date for both acquisitions was December 18, 2025.
• Mills was granted 7,758 shares of common stock (restricted stock units) at a price of $0.
• These restricted stock units vest in 12 equal monthly installments over a one-year period.
• Mills also acquired options to purchase 4,806 shares of common stock with an exercise price of $0.716.
• These options vest in 12 equal monthly installments over a one-year period and have an expiration date of December 18, 2035.

Sentiment

Score: 6

Explanation: Slightly positive. An insider acquiring equity (even if granted) generally signals alignment of interests with shareholders and confidence in the company's future, though it's a routine compensation event rather than an open market purchase.

Positives

• Director Jason Richard Mills received a grant of 7,758 restricted stock units and options for 4,806 shares, aligning his interests with shareholders.
• The vesting schedule over one year encourages long-term commitment from the director.

Future Outlook

The acquired restricted stock units and options are subject to a one-year vesting schedule, with installments occurring monthly, indicating a future increase in beneficial ownership for the director as vesting completes.

Industry Context

This Form 4 filing details a routine insider transaction, specifically an equity grant to a director, which is a common practice across various industries to incentivize and align management interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• Equity grants to directors, including restricted stock units and stock options with vesting schedules, are standard compensation practices in publicly traded companies, particularly in the medical technology sector.
• The specific terms (number of shares, exercise price, vesting period) are typically determined by the company's compensation committee based on performance, market benchmarks, and retention strategies.
• Without specific details on NeuroOne's compensation philosophy or peer group comparisons, a direct assessment against global benchmarks or comparable companies like Medtronic, Boston Scientific, or Stryker is not possible from this filing alone, but the structure of the grant is consistent with general industry norms.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value due to equity ownership and vesting incentives.
• Employees: No direct impact mentioned for general employees.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The restricted stock units will vest in 12 equal monthly installments over a one-year period.
• The options will vest in 12 equal monthly installments over a one-year period.

Key Dates

Keywords

NEUROONE MEDICAL TECHNOLOGIES, NMTC, Jason Richard Mills, Director, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Equity Grant, Vesting